Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-03-06
1997-02-25
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514653, 514654, 514655, 546329, A61K 3144, A61K 31135, C07D21373
Patent
active
056059167
ABSTRACT:
There is provided a method of treatment of neurological disorders, such as epilepsy, stroke and cerebral ischaemia, which comprises the administration of a compound of Formula I: ##STR1## wherein, Ar.sub.1 and Ar.sub.2, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of amino, nitro, halogen, hydroxy, C1 to 6 alkoxy, C1 to 6 alkyl or cyano;
R.sub.1 represents hydrogen, C1 to 6 alkyl, C1 to 6 alkoxycarbonyl;
R.sub.2 represents hydrogen or COCH.sub.2 NH.sub.2 ;
R.sub.3 represents hydrogen or C1 to 6 alkyl;
in addition, when R.sub.2 represents hydrogen either one or both of Ar.sub.1 and Ar.sub.2 may also represent 2-, 3- or 4-pyridinyl and R.sub.1 may also represent trihalomethyl;
or a pharmaceutically acceptable salt thereof.
Some of the compounds of formula I are novel, and these are also provided, together with pharmaceutical compositions containing the novel compounds.
REFERENCES:
patent: 2503285 (1950-04-01), McPhee
patent: 2604473 (1952-07-01), Sperber
patent: 3138639 (1964-06-01), Brossi et al.
patent: 3420841 (1969-01-01), Brust et al.
patent: 3471612 (1969-01-01), Goonewardene
patent: 3510560 (1970-05-01), Saunders et al.
patent: 3692784 (1972-09-01), Lindberg
patent: 3923988 (1975-12-01), Welstead, Jr. et al.
patent: 3992389 (1976-11-01), Cavalla et al.
patent: 4098764 (1978-07-01), Gencarelli et al.
patent: 4309424 (1982-01-01), Martin et al.
patent: 4769466 (1988-09-01), Griffith et al.
patent: 4798687 (1989-01-01), Griffith et al.
patent: 4822914 (1989-04-01), Martin et al.
patent: 4871872 (1989-10-01), Griffith
patent: 4873241 (1989-10-01), Napier et al.
patent: 4968721 (1990-11-01), Martin et al.
patent: 5047541 (1991-09-01), Griffith
patent: 5093524 (1992-03-01), Griffith
patent: 5292760 (1994-03-01), Martin et al.
patent: 5382683 (1995-01-01), Griffith
Sakane et al, "Preparation of dimethoxydeoxybenzoin oxine derwaters as intermediates for optically active 1,2-bis(4-methoxy phenyl) ethylamine", CA 120: 191 318, (1994).
CA 64,14162f, abstracting Zaheer et al., Ann. Chem. 691, 55-60 (1966).
CA 73,25044n, abstracting Novelli et al., Bol. Soc. Quim Peru, 35(3), 77-84 (1969).
CA 77,19586, abstracting Patel et al., J. Indian Chem. Soc. 49(2) 177-80 (1972).
CA 85,5705y, abstracting Japan Kokai 50/130776 (1975).
CA 96,19744z, abstracting Antoniadau-Vyza et al, Prakt. Akad. Athenon 54 (A-B), 383-97 (1980).
Hubsch et al., "Determination of 2-Amino-N(1-Methyl-1,2-Diphenylethyl) Acetamide Monohydrochloride From a Ground Beef Matrix High Performance Liquid Chromatography", Abst. 127, Northeast Regional Meeting of the Am. Chem. Soc., Rochester, NY, Nov. 19, 1987.
Palmer et al., "A New Anticonvulsant, PR 934-423 Active Against Maximal Electroshock Seizures I: Mice Studies" Abst. 317.15, Society of Neuroscience Meetings, LA (Nov. 16, 1987).
Colombo et al., "A New Anticonvulsant, PR 934-423, Active Against Maximal Electroshock Seizures II: Rat Studies", Abst. 317.16, Society of Neuroscience Meetings, LA (Nov. 16, 1987).
Freedman et al., "A New Anticonvulsant, PR 934-423, Active Against Maximal Electroshock Seizures III: Electrophysiological Studies", Abst. 317.17 Society of Neuroscience Meetings, New Orleans, LA (Nov. 16, 1987).
Luke et al., "Toxicity of a Novel Anticonvulsant, 2-Amino-N-(2-Methyl-1,2-Diphenylethyl) Acetamides PR 934-423A" Abst. Society of Toxicology Annual Meeting, Dallas, Tx. (Feb. 15, 1988).
Griffith et al., "Synthesis and Anticonvulsant Activity of a Series of 2-Amino-N-(1,2-Diphenylethyl) Acetamides" Abst. 196th Natl. Meeting of the Am. Chem. Soc., Los Angeles, CA (Sep. 25-29, 1988).
Garske et al., "Preclinical Profile of Isomers of the Anticonvulsant PR 934-423", Society of Neuroscience Meeting, Toronto, Ont., Can. (Nov. 1988).
Stagnitto et al., "PR 1013-708, A Potent Anticonvulsant Against Maximal Electroshock Seizures (MES) in Rodents", Abs. Society of Neuroscience Meeting, Toronto, Ont., Can. (Nov. 1988).
Wilson et al., "Anticonvulsant Concentrations in CSF and Serum of Rats Protected Against MES by PR 934-423A", Abs. Society of Neuroscience Meeting, Toronto, Ont., Can. (Nov. 1988).
Palmer et al., "Status of PR 934-423. A Novel Anticonvulsant Targeted for Generalized Toxic/Clinic Seizures New Designation is FPL 12924AA", Abs. Princeton Symposium, NJ (May 1989).
Gosh et al., Arzneim-Forch/Drug Res. 28 (11) Heft 9 (1978) pp. 1561-1564.
Winn et al., J. Org. Chem., 33(6), 2388-92 (1968).
CA 84(9):59216n, abstracting German Offen. DE 2415063 (1976).
CA 104(17):148472s, abstracting U.S. Patent 4,536,599 (1986).
Medical Subject Headings, Tree Structures, 1992, pp. 165-174.
Dodds, Lawson & Williams, Royal Society Journal, 1943.
Shimada et al., Chem. Pharm. Bull. 32(12) 4893-906 (1984).
Niemers et al., Synthesis (9), 593-5 (1976).
Coughenour et al., Pharm. Biochem. & Behavior, vol. 6, pp. 351-353 (1977).
Porter et al., Cleveland Clinic Quarterly, 51:293-305, (Summer 1984).
Griffith Ronald C.
Napier James J.
Astra AB
Lambkin Deborah
Raymond Richard L.
LandOfFree
Arylalkyl-amines having anticonvulsant and neuroprotective prope does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylalkyl-amines having anticonvulsant and neuroprotective prope, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylalkyl-amines having anticonvulsant and neuroprotective prope will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1974252